A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2004 by Trimeris.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Trimeris
ClinicalTrials.gov Identifier:
NCT00048217
First received: October 28, 2002
Last updated: June 23, 2005
Last verified: July 2004
  Purpose

Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.


Condition Intervention Phase
HIV Infections
Drug: T-1249
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Trimeris:

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Completion T1249-102;
  • Currently failing a T-20 containing regimen

Exclusion Criteria:

  • Non-completion of T1249-102.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00048217

Locations
United States, North Carolina
Trimeris
Durham, North Carolina, United States, 27707
Sponsors and Collaborators
Trimeris
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00048217     History of Changes
Other Study ID Numbers: T1249-105
Study First Received: October 28, 2002
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Trimeris:
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on July 28, 2014